Search

Your search keyword '"Franken, L. C."' showing total 10 results
Start Over Author "Franken, L. C."
10 results on '"Franken, L. C."'

2. Value of routine intraoperative frozen sections of proximal bile duct margins in perihilar cholangiocarcinoma, a retrospective multicenter and matched case-control study

Author

Nooijen, L. E., Franken, L. C., de Boer, M. T., Buttner, S., van Dieren, S., Koerkamp, B. Groot, Hoogwater, F. J.H., Kazemier, G., Klümpen, H. J., Kuipers, H., Olthof, P. B., Swijnenburg, R. J., Verheij, J., Zonderhuis, B. M., van Gulik, T. M., Erdmann, J. I., Nooijen, L. E., Franken, L. C., de Boer, M. T., Buttner, S., van Dieren, S., Koerkamp, B. Groot, Hoogwater, F. J.H., Kazemier, G., Klümpen, H. J., Kuipers, H., Olthof, P. B., Swijnenburg, R. J., Verheij, J., Zonderhuis, B. M., van Gulik, T. M., and Erdmann, J. I.

Abstract

Background: Currently, the potential benefits of additional resection after positive proximal intraoperative frozen sections (IFS) in perihilar cholangiocarcinoma (pCCA) on residual disease and oncological outcome remain uncertain. Therefore, the aim of this study is to investigate the number of R0 resections after additional resection of a positive proximal IFS and the influence of additional resections on overall survival (OS) in patients with pCCA. Materials and methods: A retrospective, multicenter, matched case-control study was performed, including patients undergoing resection for pCCA between 2000 and 2019 at three tertiary centers. Primary outcome was the number of achieved ‘additional’ R0 resections. Secondary outcomes were OS, recurrence, severe morbidity and mortality. Results: Forty-four out of 328 patients undergoing resection for pCCA had a positive proximal IFS. An additional resection was performed in 35 out of 44 (79.5%) patients, which was negative in 24 (68.6%) patients. Nevertheless, seven out of these 24 patients were eventually classified as R1 resection due to other positive resection margins. Therefore, 17 (48.6%) patients could be classified as “true” R0 resection after additional resection. Ninety-day mortality after R1 resections was high (25%) and strongly influenced OS. After correction for 90-day mortality, median OS after negative additional resection was 33 months (95%CI:29.5–36.5) compared to 30 months (95%CI:24.4–35.6) after initial R1 (P = 0.875) and 46 months (95%CI:32.7–59.3) after initial R0 (P = 0.348). Conclusion: There were only 17 patients (out of a total of 328 patients) that potentially benefitted from routine IFS. Additional resection for a positive IFS leading to R0 resection was not associated with improved long-term survival.

Published
2022

3. Correction to: Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma (Annals of Surgical Oncology, (2020), 10.1245/s10434-020-08258-3)

Author

Olthof P. B., Aldrighetti L., Alikhanov R., Cescon M., Groot Koerkamp B., Jarnagin W. R., Nadalin S., Pratschke J., Schmelzle M., Sparrelid E., Lang H., Guglielmi A., van Gulik T. M., Andreou A., Bartsch F., Benzing C., Buettner S., Capobianco I., de Reuver P., de Savornin Lohman E., Dejong C. H. C., Efanov M., Erdmann J. I., Franken L. C., Frascaroli G., Giglio M. C., Gomez-Gavara C., Heid F., IJzermans J. N. M., Jansson H., Ligthart M. A. P., Maithel S. K., Malago M., Malik H. Z., Muiesan P., Olde Damink S. W. M., Pando E., Quinn L. M., Ratti F., Roberts K. J., Rolinger J., Ruzzenente A., Schadde E., Serenari M., Sultana A., Troisi R., van Laarhoven S., van Vugt J. L. A., Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelzle, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., Ijzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., and van Vugt, J. L. A.

Abstract

In the original article Moritz Schmelzle’s last name is spelled wrong. It is correct as reflected here.

Published
2020

4. Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma

Author

Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelze, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., IJzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., van Vugt, J. L. A., Surgery, Academic Medical Center, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelze, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., Ijzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., and van Vugt, J. L. A.

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, education, 030230 surgery, Preoperative care, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, Retrospective Studie, Preoperative Care, medicine, Hepatectomy, Humans, Embolization, Abscess, Bile Duct Neoplasm, Aged, Retrospective Studies, portal vein embolization, portal vein embolisation, Perihilar cholangiocarcinoma, Portal Vein, business.industry, Incidence (epidemiology), Liver Neoplasms, Correction, Retrospective cohort study, Middle Aged, Jaundice, medicine.disease, Embolization, Therapeutic, Surgery, Bile Duct Neoplasms, Oncology, Liver Neoplasm, Hepatobiliary Tumors, 030220 oncology & carcinogenesis, Propensity score matching, Cohort, medicine.symptom, business, Liver Failure, Human, Klatskin Tumor
Abstract

Background Preoperative portal vein embolization (PVE) is frequently used to improve future liver remnant volume (FLRV) and to reduce the risk of liver failure after major liver resection. Objective This paper aimed to assess postoperative outcomes after PVE and resection for suspected perihilar cholangiocarcinoma (PHC) in an international, multicentric cohort. Methods Patients undergoing resection for suspected PHC across 20 centers worldwide, from the year 2000, were included. Liver failure, biliary leakage, and hemorrhage were classified according to the respective International Study Group of Liver Surgery criteria. Using propensity scoring, two equal cohorts were generated using matching parameters, i.e. age, sex, American Society of Anesthesiologists classification, jaundice, type of biliary drainage, baseline FLRV, resection type, and portal vein resection. Results A total of 1667 patients were treated for suspected PHC during the study period. In 298 patients who underwent preoperative PVE, the overall incidence of liver failure and 90-day mortality was 27% and 18%, respectively, as opposed to 14% and 12%, respectively, in patients without PVE (p p = 0.005). After propensity score matching, 98 patients were enrolled in each cohort, resulting in similar baseline and operative characteristics. Liver failure was lower in the PVE group (8% vs. 36%, p p p = 0.01), and 90-day mortality (7% vs. 18%, p = 0.03). Conclusion PVE before major liver resection for PHC is associated with a lower incidence of liver failure, biliary leakage, abscess formation, and mortality. These results demonstrate the importance of PVE as an integral component in the surgical treatment of PHC.

Published
2020

7. Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study

Author

F. Bartsch, J. Hagendoorn, R. Charco, Q.I. Molenaar, Hauke Lang, A. Sultana, F. Heid, J.I. Erdmann, Erik Schadde, G. Kazemier, H.Z. Malik, J. Rolinger, Stefan Buettner, C.L.M. Nota, Andrea Ruzzenente, M.C. Giglio, Mikhail Efanov, Shishir K. Maithel, P. Muiesan, M. Ravaioli, K.J. Roberts, I. Capobianco, Thomas M. van Gulik, J. van Vugt, Ruslan Alikhanov, Hannes Jansson, A. Andreou, Alfredo Guglielmi, Johann Pratschke, M. Malago, Moritz Schmelzle, E. de Savornin Lohman, Silvio Nadalin, Marjolein A P Ligthart, P.R. de Reuver, Bas Groot Koerkamp, S. W. M. Olde Damink, L.E. Nooijen, Francesca Ratti, S. van Laarhoven, C. Gomez-Gavara, B.M. Zonderhuis, C. Benzing, Matteo Serenari, Luca Aldrighetti, L.C. Franken, Annika Bergquist, Cornelis H. C. Dejong, Ernesto Sparrelid, Matteo Cescon, William R. Jarnagin, L.M. Quinn, Pim B. Olthof, J.N.M. IJzermans, Roberto Troisi, RS: NUTRIM - R2 - Liver and digestive health, Surgery, MUMC+: MA Heelkunde (9), Jansson, H., Olthof, P. B., Bergquist, A., Ligthart, M. A. P., Nadalin, S., Troisi, R, Groot Koerkamp, B., Alikhanov, R., Lang, H., Guglielmi, A., Cescon, M., Jarnagin, W. R., Aldrighetti, L., van Gulik, T. M., Sparrelid, E., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., Charco, R., de Reuver, P. R., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Giglio, M. C., Gomez-Gavara, C., Hagendoorn, J., Heid, F., Ijzermans, J. N. M., Kazemier, G., Maithel, S. K., Malago, M., Malik, H. Z., Molenaar, Q. I., Muiesan, P., Nooijen, L. E., Nota, C. L. M., Olde Damink, S. W. M., Pratschke, J., Quinn, L. M., Ratti, F., Ravaioli, M., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Schmelzle, M., Serenari, M., Sultana, A., van Laarhoven, S., van Vugt, J. L. A., Zonderhuis, B. M., Troisi, R. I., CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
medicine.medical_specialty, endocrine system diseases, Cholangitis, Cholangitis, Sclerosing, 030230 surgery, HILAR CHOLANGIOCARCINOMA, Gastroenterology, digestive system, Article, Sclerosing, Resection, Primary sclerosing cholangitis, Cholangiocarcinoma, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Primary outcome, Internal medicine, Overall survival, medicine, Humans, In patient, Perihilar Cholangiocarcinoma, Retrospective Studies, Intrahepatic, RISK, Hepatology, business.industry, digestive, oral, and skin physiology, Retrospective cohort study, medicine.disease, digestive system diseases, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Postoperative mortality, 030220 oncology & carcinogenesis, Bile Ducts, business, Klatskin Tumor
Abstract

Contains fulltext : 245473.pdf (Publisher’s version ) (Open Access) BACKGROUND: Resection for perihilar cholangiocarcinoma (pCCA) in primary sclerosing cholangitis (PSC) has been reported to lead to worse outcomes than resection for non-PSC pCCA. The aim of this study was to compare prognostic factors and outcomes after resection in patients with PSC-associated pCCA and non-PSC pCCA. METHODS: The international retrospective cohort comprised patients resected for pCCA from 21 centres (2000-2020). Patients operated with hepatobiliary resection, with pCCA verified by histology and with data on PSC status, were included. The primary outcome was overall survival. Secondary outcomes were disease-free survival and postoperative complications. RESULTS: Of 1128 pCCA patients, 34 (3.0%) had underlying PSC. Median overall survival after resection was 33 months for PSC patients and 29 months for non-PSC patients (p = .630). Complications (Clavien-Dindo grade ≥ 3) were more frequent in PSC pCCA (71% versus 44%, p = .003). The rate of posthepatectomy liver failure (21% versus 17%, p = .530) and 90-day mortality (12% versus 13%, p = 1.000) was similar for PSC and non-PSC patients. CONCLUSION: Median overall survival after resection for pCCA was similar in patients with underlying PSC and non-PSC patients. Complications were more frequent after resection for PSC-associated pCCA, with no difference in postoperative mortality.

Published
2021

8. Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group

Author

Ruzzenente, Andrea, Bagante, Fabio, Olthof, Pim B, Aldrighetti, Luca, Alikhanov, Ruslan, Cescon, Matteo, Koerkamp, Bas Groot, Jarnagin, William R, Nadalin, Silvio, Pratschke, Johann, Schmelzle, Moritz, Sparrelid, Ernesto, Lang, Hauke, Iacono, Calogero, van Gulik, Thomas M, Guglielmi, Alfredo, Andreou A, Bartsch F, Benzing C, Buettner S, Campagnaro T, Capobianco I, Charco R, de Reuver P, de Savornin, Lohman E, Nijmegen, Dejong CHC, Efanov M, Erdmann JI, Franken LC, Giovinazzo G, Giglio MC, Gomez-Gavara C, Heid F, IJzermans JNM, Isaac J, Jansson H, Ligthart MAP, Maithel SK, Malago` M. Malik HZ, Muiesan P, Olde Damink SWM, Quinn LM, Ratti F, Ravaioli M, Rolinger J, Schadde E, Serenari M, Troisi R, van Laarhoven S, van Vugt JLA, Faculteit Medische Wetenschappen/UMCG, Surgery, Ruzzenente, Andrea, Bagante, Fabio, Olthof, Pim B, Aldrighetti, Luca, Alikhanov, Ruslan, Cescon, Matteo, Koerkamp, Bas Groot, Jarnagin, William R, Nadalin, Silvio, Pratschke, Johann, Schmelzle, Moritz, Sparrelid, Ernesto, Lang, Hauke, Iacono, Calogero, van Gulik, Thomas M, Guglielmi, Alfredo, Andreou, A, Bartsch, F, Benzing, C, Buettner, S, Campagnaro, T, Capobianco, I, Charco, R, de Reuver, P, De, Savornin, Lohman, E, Nijmegen, Dejong, Chc, Efanov, M, Erdmann, Ji, Franken, Lc, Giovinazzo, G, Giglio, Mc, Gomez-Gavara, C, Heid, F, Ijzermans, Jnm, Isaac, J, Jansson, H, Ligthart, Map, Maithel, Sk, Malago` M., Malik HZ, Muiesan, P, Olde Damink, Swm, Quinn, Lm, Ratti, F, Ravaioli, M, Rolinger, J, Schadde, E, Serenari, M, Troisi, R, van Laarhoven, S, van Vugt, Jla, Ruzzenente, A., Bagante, F., Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Koerkamp, B. G., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelzle, M., Sparrelid, E., Lang, H., Iacono, C., van Gulik, T. M., Guglielmi, A., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Campagnaro, T., Capobianco, I., Charco, R., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Giovinazzo, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., Ijzermans, J. N. M., Isaac, J., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Damink, S. W. M. O., Quinn, L. M., Ratti, F., Ravaioli, M., Rolinger, J., Schadde, E., Serenari, M., Troisi, R., van Laarhoven, S., van Vugt, J. L. A., CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
medicine.medical_specialty, medicine.medical_treatment, Perineural invasion, Metastasis, Cholangiocarcinoma, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Surgical oncology, Medicine, Hepatectomy, Humans, Perihilar Cholangiocarcinoma, Contraindication, Retrospective Studies, business.industry, Incidence (epidemiology), medicine.disease, Surgery, Oncology, Bile Duct Neoplasms, Cohort, business, Bismuth, Klatskin Tumor
Abstract

Background Although Bismuth-Corlette (BC) type 4 perihilar cholangiocarcinoma (pCCA) is no longer considered a contraindication for curative surgery, few data are available from Western series to indicate the outcomes for these patients. This study aimed to compare the short- and long-term outcomes for patients with BC type 4 versus BC types 2 and 3 pCCA undergoing surgical resection using a multi-institutional international database. Methods Uni- and multivariable analyses of patients undergoing surgery at 20 Western centers for BC types 2 and 3 pCCA and BC type 4 pCCA. Results Among 1138 pCCA patients included in the study, 826 (73%) had BC type 2 or 3 disease and 312 (27%) had type 4 disease. The two groups demonstrated significant differences in terms of clinicopathologic characteristics (i.e., portal vein embolization, extended hepatectomy, and positive margin). The incidence of severe complications was 46% for the BC types 2 and 3 patients and 51% for the BC type 4 patients (p = 0.1). Moreover, the 90-day mortality was 13% for the BC types 2 and 3 patients and 12% for the BC type 4 patients (p = 0.57). Lymph-node metastasis (N1; hazard-ratio [HR], 1.62), positive margins (R1; HR, 1.36), perineural invasion (HR, 1.53), and poor grade of differentiation (HR, 1.25) were predictors of survival (all p ≤0.004), but BC type was not associated with prognosis. Among the N0 and R0 patients, the 5-year overall survival was 43% for the patients with BC types 2 and 3 pCCA and 41% for those with BC type 4 pCCA (p = 0.60). Conclusions In this analysis of a large Western multi-institutional cohort, resection was shown to be an acceptable curative treatment option for selected patients with BC type 4 pCCA although a more technically challenging surgical approach was required.

Published
2020

9. Value of routine intraoperative frozen sections of proximal bile duct margins in perihilar cholangiocarcinoma, a retrospective multicenter and matched case-control study.

Author

Nooijen LE, Franken LC, de Boer MT, Buttner S, van Dieren S, Koerkamp BG, Hoogwater FJH, Kazemier G, Klümpen HJ, Kuipers H, Olthof PB, Swijnenburg RJ, Verheij J, Zonderhuis BM, van Gulik TM, and Erdmann JI

Subjects
Humans, Retrospective Studies, Case-Control Studies, Frozen Sections, Bile Ducts pathology, Bile Duct Neoplasms pathology, Klatskin Tumor pathology, Cholangiocarcinoma surgery
Abstract

Background: Currently, the potential benefits of additional resection after positive proximal intraoperative frozen sections (IFS) in perihilar cholangiocarcinoma (pCCA) on residual disease and oncological outcome remain uncertain. Therefore, the aim of this study is to investigate the number of R0 resections after additional resection of a positive proximal IFS and the influence of additional resections on overall survival (OS) in patients with pCCA., Materials and Methods: A retrospective, multicenter, matched case-control study was performed, including patients undergoing resection for pCCA between 2000 and 2019 at three tertiary centers. Primary outcome was the number of achieved 'additional' R0 resections. Secondary outcomes were OS, recurrence, severe morbidity and mortality., Results: Forty-four out of 328 patients undergoing resection for pCCA had a positive proximal IFS. An additional resection was performed in 35 out of 44 (79.5%) patients, which was negative in 24 (68.6%) patients. Nevertheless, seven out of these 24 patients were eventually classified as R1 resection due to other positive resection margins. Therefore, 17 (48.6%) patients could be classified as "true" R0 resection after additional resection. Ninety-day mortality after R1 resections was high (25%) and strongly influenced OS. After correction for 90-day mortality, median OS after negative additional resection was 33 months (95%CI:29.5-36.5) compared to 30 months (95%CI:24.4-35.6) after initial R1 (P = 0.875) and 46 months (95%CI:32.7-59.3) after initial R0 (P = 0.348)., Conclusion: There were only 17 patients (out of a total of 328 patients) that potentially benefitted from routine IFS. Additional resection for a positive IFS leading to R0 resection was not associated with improved long-term survival., Competing Interests: Declaration of competing interest None., (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2022
Full Text
View/download PDF

10. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC.

Author

Franken LC, Vuijk FA, Soer EC, Roos E, Erdmann JI, Hooijer GKJ, Vahrmeijer AL, Gambhir SS, van Gulik TM, Sarasqueta AF, Verheij J, and Swijnenburg RJ

Subjects
Bile Duct Neoplasms diagnosis, Bile Duct Neoplasms pathology, Bile Ducts, Intrahepatic, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular pathology, Cholangiocarcinoma diagnosis, Cholangiocarcinoma pathology, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Klatskin Tumor diagnosis, Klatskin Tumor pathology, Liver Diseases diagnosis, Liver Diseases metabolism, Liver Diseases pathology, Liver Neoplasms diagnosis, Liver Neoplasms pathology, Male, Middle Aged, Molecular Imaging, Optical Imaging, Positron Emission Tomography Computed Tomography, Tissue Array Analysis, Antigens, Neoplasm metabolism, Bile Duct Neoplasms metabolism, Carcinoma, Hepatocellular metabolism, Cholangiocarcinoma metabolism, Integrins metabolism, Klatskin Tumor metabolism, Liver Neoplasms metabolism
Abstract

Background: Approximately 15% of patients undergoing resection for presumed perihilar cholangiocarcinoma (PHC) have benign disease at final pathological assessment. Molecular imaging targeting tumor-specific biomarkers could serve as a novel diagnostic tool to reduce these futile surgeries. Imaging agents have been developed, selectively binding integrin α ν β 6, a cell receptor upregulated in pancreatobiliary malignancies, for both (preoperative) PET and (intraoperative) fluorescent imaging. Here, expression of integrin α ν β 6 is evaluated in PHC, intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC) and benign disease mimicking PHC using immunohistochemistry., Materials & Methods: Three tissue microarrays (TMA) including 103 PHC tumor cores and sixty tissue samples were selected from resection specimens of pathologically proven PHC (n = 20), ICC (n = 10), HCC (n = 10), metastatic PHC lymph nodes (n = 10) and benign disease (presumed PHC with benign disease at pathological assessment, n = 10). These samples were stained for integrin α ν β 6 and quantified using the H-score., Results: Immunohistochemical staining for integrin α ν β 6 showed membranous expression in all twenty PHC whole mount slides (100%) and 93 out of 103 (92%) PHC tumor cores. Mean H-score of PHC samples was 195 ± 71, compared to a mean H-score of 126 ± 57 in benign samples (p = 0.013). In both benign and PHC samples, inflammatory infiltrates and pre-existent peribiliary glands showed integrin α ν β 6 expression. The mean H-score across ten ICC was 33 ± 53, which was significantly lower compared to PHC (p < 0.001) but too weak to consistently discriminate ICC from HCC (H-score 0)(p = 0.062)., Conclusion: Integrin α ν β 6 is abundantly expressed in PHC and associated metastatic lymph nodes. Expression is significantly higher in PHC as compared to benign disease mimicking PHC, ICC and HCC, emphasizing its potential as a target for tumor-specific molecular imaging., Competing Interests: Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results